Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gastrointestinal 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 9Specimen Handling 7tislelizumab 6Pemetrexed 6Cisplatin 6Carboplatin 6fludarabine 5atezolizumab 5Interviews as Topic 5Injections 5Cyclophosphamide 5Bevacizumab 5Platinum 4Fluorouracil 4Educational Status 4Biopsy 4Standard of Care 3Practice Guidelines as Topic 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Early Intervention, Educational 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2fludarabine phosphate 2X-Rays 2Trastuzumab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CT-P6 × Other solid neoplasm × 30 days × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡